Influence of IL-38 as a novel biomarker on the pathophysiological processes of esophageal cancer

IF 1.4 4区医学 Q4 GENETICS & HEREDITY

Cancer Genetics Pub Date : 2025-07-03 DOI:10.1016/j.cancergen.2025.06.010

Dehua Zeng , Shixin Ye , Wenmin Yin , Duohuang Lian , Shunkai Zhou

{"title":"Influence of IL-38 as a novel biomarker on the pathophysiological processes of esophageal cancer","authors":"Dehua Zeng , Shixin Ye , Wenmin Yin , Duohuang Lian , Shunkai Zhou","doi":"10.1016/j.cancergen.2025.06.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to identify biomarkers of esophageal cancer and elucidate their mechanisms of action in esophageal cancer.</div></div><div><h3>Methods</h3><div>Differential protein expression between esophageal tumor tissue and adjacent normal tissue was analyzed using proteomics in a mouse model of esophageal cancer. Differential proteins were identified through bioinformatics analysis. The mechanisms of action of differential proteins in esophageal cancer were validated using techniques such as western blotting and immunohistochemistry.</div></div><div><h3>Results</h3><div>Proteomic analysis revealed that IL-38 exhibited the greatest differential expression. Molecular biology techniques including western blotting and immunohistochemistry demonstrated that IL-38 modulates Regulatory T cell (Treg)/ T helper 17 cell (Th17) balance through the Sirtuin 1 (SIRT1)/ hypoxia-inducible factor 1-alpha (HIF-1α) signaling pathway in esophageal cancer.</div></div><div><h3>Conclusion</h3><div>IL-38 is a novel biomarker for esophageal cancer and regulates Treg/Th17 balance through the Sirt1/HIF-1α signaling pathway, providing new insights for the treatment of esophageal cancer.</div></div>","PeriodicalId":49225,"journal":{"name":"Cancer Genetics","volume":"296 ","pages":"Pages 117-124"},"PeriodicalIF":1.4000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Genetics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2210776225000791","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This study aimed to identify biomarkers of esophageal cancer and elucidate their mechanisms of action in esophageal cancer.

Methods

Differential protein expression between esophageal tumor tissue and adjacent normal tissue was analyzed using proteomics in a mouse model of esophageal cancer. Differential proteins were identified through bioinformatics analysis. The mechanisms of action of differential proteins in esophageal cancer were validated using techniques such as western blotting and immunohistochemistry.

Results

Proteomic analysis revealed that IL-38 exhibited the greatest differential expression. Molecular biology techniques including western blotting and immunohistochemistry demonstrated that IL-38 modulates Regulatory T cell (Treg)/ T helper 17 cell (Th17) balance through the Sirtuin 1 (SIRT1)/ hypoxia-inducible factor 1-alpha (HIF-1α) signaling pathway in esophageal cancer.

Conclusion

IL-38 is a novel biomarker for esophageal cancer and regulates Treg/Th17 balance through the Sirt1/HIF-1α signaling pathway, providing new insights for the treatment of esophageal cancer.

查看原文本刊更多论文

IL-38作为新型生物标志物对食管癌病理生理过程的影响

目的鉴定食管癌的生物标志物，探讨其在食管癌中的作用机制。方法采用蛋白质组学方法分析食管癌小鼠模型中食管癌组织与邻近正常组织的蛋白表达差异。通过生物信息学分析鉴定差异蛋白。利用western blotting和免疫组织化学等技术验证了差异蛋白在食管癌中的作用机制。结果蛋白质组学分析显示IL-38的表达差异最大。western blotting和免疫组化等分子生物学技术表明，IL-38通过SIRT1 / HIF-1α信号通路调节食管癌中调节性T细胞(Treg)/辅助性T细胞（Th17）的平衡。结论il -38是食管癌的新型生物标志物，通过Sirt1/HIF-1α信号通路调控Treg/Th17平衡，为食管癌的治疗提供新的思路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Genetics ONCOLOGY-GENETICS & HEREDITY

CiteScore

3.20

自引率

5.30%

发文量

167

审稿时长

27 days

期刊介绍： The aim of Cancer Genetics is to publish high quality scientific papers on the cellular, genetic and molecular aspects of cancer, including cancer predisposition and clinical diagnostic applications. Specific areas of interest include descriptions of new chromosomal, molecular or epigenetic alterations in benign and malignant diseases; novel laboratory approaches for identification and characterization of chromosomal rearrangements or genomic alterations in cancer cells; correlation of genetic changes with pathology and clinical presentation; and the molecular genetics of cancer predisposition. To reach a basic science and clinical multidisciplinary audience, we welcome original full-length articles, reviews, meeting summaries, brief reports, and letters to the editor.